Clinical Trial: Bortezomib in Treating Patients With Mantle Cell Lymphoma

This study is no longer recruiting patients.

Sponsored by: National Cancer Institute of Canada
Information provided by: National Cancer Institute (NCI)


RATIONALE: Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.

PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have previously untreated or relapsedmantle cell lymphoma.

Condition Treatment or Intervention Phase
stage I mantle cell lymphoma
contiguous stage II mantle cell lymphoma
noncontiguous stage II mantle cell lymphoma
stage III mantle cell lymphoma
stage IV mantle cell lymphoma
recurrent mantle cell lymphoma
 Drug: bortezomib
 Procedure: enzyme inhibitor therapy
Phase II

MedlinePlus related topics:  Lymphoma

Study Type: Interventional
Study Design: Treatment

Official Title: Phase II Study of Bortezomib in Patients With Previously Untreated or Relapsed Mantle Cell Lymphoma

Further Study Details: 


  • Determine the efficacy of bortezomib, in terms of response rate, in patients with previously untreated or relapsed mantle cell lymphoma.
  • Determine the toxicity of this drug in these patients.
  • Correlate suppression of 20S proteasome levels with toxicity of and response to this drug in these patients.
  • Determine the time to progression and response duration in patients treated with this drug.

OUTLINE: This is a nonrandomized, multicenter study.

Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients with complete response (CR) receive 2 courses beyond documentation of CR. Patients with stable disease receive a maximum of 4 courses. Patients with partial response (PR) continue therapy until disease progression or for 2 courses beyond documentation of stable PR.

Patients are followed at 4 weeks and then every 3 months until disease progression.

PROJECTED ACCRUAL: A total of 14-30 patients will be accrued for this study within 18-24 months.


Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both



  • Histologically or cytologically confirmed relapsed or untreated mantle cell lymphoma
  • No refractory disease defined as progression while on chemotherapy or within 1 month after completion of chemotherapy
  • At least 1 bidimensionally measurable disease site*
  • Lymph nodes at least 1.5 cm by 1.5 cm by spiral CT scan OR
  • Non-nodal lesions (e.g., skin lesion or nodules) at least 1 cm by 1 cm by MRI, CT scan, or physical exam NOTE: *Bone lesions are not considered bidimensionally measurable disease
  • No pre-existing ascites or pleural effusion
  • No known CNS involvement by lymphoma


  • 18 and over

Performance status:

  • ECOG 0-2

Life expectancy:

  • At least 12 weeks


  • Absolute granulocyte count at least 1,500/mm^3
  • Platelet count at least 75,000/mm^3


  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • AST or ALT no greater than 2.5 times ULN


  • Creatinine no greater than 1.5 times ULN


  • LVEF at least 45% by echocardiogram or MUGA


  • No pre-existing shortness of breath greater than grade 1


  • No uncontrolled bacterial, fungal, or viral infections
  • No pre-existing edema greater than grade 1
  • No pre-existing neuropathy greater than grade 1
  • No other malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or carcinoma in situ of the cervix
  • No other serious illness or medical condition that would preclude study compliance
  • No geographical conditions that would preclude study compliance
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception



Endocrine therapy:

  • No concurrent corticosteroids


  • No prior radiotherapy to 25% or more of functioning bone marrow
  • At least 4 weeks since prior radiotherapy (except low-dose nonmyelosuppressive radiotherapy) and recovered
  • No concurrent radiotherapy to the sole site of measurable disease


  • At least 2 weeks since prior major surgery


Location Information

Canada, Alberta
      Cross Cancer Institute, Edmonton,  Alberta,  T6G 1Z2,  Canada

Canada, British Columbia
      British Columbia Cancer Agency, Vancouver,  British Columbia,  V5Z 4E6,  Canada

Canada, Manitoba
      CancerCare Manitoba, Winnipeg,  Manitoba,  R3E 0V9,  Canada

Canada, Ontario
      Cancer Care Ontario-London Regional Cancer Centre, London,  Ontario,  N6A 4L6,  Canada

      Kingston Regional Cancer Centre, Kingston,  Ontario,  K7L 5P9,  Canada

      Margaret and Charles Juravinski Cancer Centre, Hamilton,  Ontario,  L8V 5C2,  Canada

      Princess Margaret Hospital, Toronto,  Ontario,  M5G 2M9,  Canada

      Toronto Sunnybrook Regional Cancer Centre, Toronto,  Ontario,  M4N 3M5,  Canada

Canada, Quebec
      Maisonneuve-Rosemont Hospital, Montreal,  Quebec,  H1T 2M4,  Canada

      McGill University, Montreal,  Quebec,  H2W 1S6,  Canada

Study chairs or principal investigators

Andrew R. Belch, MD,  Study Chair,  Cross Cancer Institute   

More Information

Clinical trial summary from the National Cancer Institute's PDQ® database

Study ID Numbers:  CDR0000069207; CAN-NCIC-IND150
Record last reviewed:  September 2004
Last Updated:  October 13, 2004
Record first received:  February 14, 2002 Identifier:  NCT00030875
Health Authority: Unspecified processed this record on 2005-04-08

Cache Date: April 9, 2005